David Baker, MBA
CHIEF EXECUTIVE OFFICER, VALLON PHARMA
Philadelphia, Pennsylvania, United States
David is a co-founder of Vallon and has 30 years of executive, operational and commercial leadership experience in the pharmaceutical industry. He has been directly involved with the commercialization of five medications with annual sales in excess of $1 billion each, including Adderall XR® and Vyvanse®, the two most successful ADHD brands. Previously, David was the Chief Commercial Officer and interim CEO of Alcobra Ltd., a CNS specialty pharmaceutical company that completed a reverse merger with Arcturus Therapeutics in 2017. Prior to Alcobra, he worked at Shire Plc for 10 years as Vice President of Commercial Strategy in the Neuroscience Business Unit, Global General Manager for Vyvanse® and Vice President, ADHD Marketing. Prior to Shire, he worked at Merck & Co. for 14 years in various commercial roles. Mr. Baker earned a bachelor’s degree in Economics and Computer Science from Duke University, and an MBA in Marketing, from Duke’s Fuqua School of Business.